ABCL operates in the Biotechnology industry. The company generates approximately $75.13 million in revenue. Net loss totals approximately $146.41 million, while roughly $868.21 million in cash on hand.
As of May 7, 2026, Abcellera Biologics is priced at $5.04, reflecting a 8.15% increase today after opening at $4.66. Current risk models assign Abcellera Biologics a 21% probability of financial distress, reflecting a moderate probability within its current risk profile. Return data over the last 90 trading days classifies Abcellera Biologics as constructive in terms of performance. The performance scores reflect data spanning February 6, 2026 through May 7, 2026. Learn more.
Abcellera Biologics (ABCL) is listed on NASDAQ Exchange in USA. ABCL conducts business in the Health Care industry (Biotechnology sector). Abcellera Biologics carries a mid-cap market capitalization of $1.4 billion when compared with health care companies. The broader capitalization picture also reflects enterprise value near $1.01 billion, a workforce of about 562 people, and operating in the Health Care industry. Abcellera Biologics has 305.26 million shares outstanding, with 47.7 million shares sold short (19.02 days to cover). A negative net margin of 1.95% indicates the company is not currently profitable on a net income basis. Abcellera Biologics is an operator in the health care segment where revenue is driven by core operating activity and end-market demand. ABCL has a beta of 2.1306. With a beta above 1, Abcellera Biologics typically delivers outsized gains in rising markets at the cost of steeper drawdowns. Abcellera Biologics financial stability analysisOwnership Allocation Abcellera Biologics carries a considerable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Abcellera Ownership Details
Rational investors seek to maximize expected return while keeping volatility in check. The Abcellera Biologics market risk premium quantifies the additional return investors require above the risk-free rate. For Abcellera Biologics, the CAPM framework translates risk exposure into a quantitative expected return measure. The CAPM framework provides the foundation for comparing Abcellera Biologics to other equity alternatives.
Abcellera Biologics is scheduled to announce its earnings today. Abcellera Biologics develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics employs 562 people. Headquarters are in 150 W 4th Avenue, Vancouver, BC, Canada, V5Y 1G6. Recent market snapshot indicates market cap 1.4 billion, P/E 16.67. As a small-cap equity, Abcellera Biologics is evaluated across valuation, solvency, and efficiency signals. Operating metrics are tied to how the market is pricing risk. Higher trading volume may improve order execution and price continuity.
Methodology
Unless otherwise specified, financial data for Abcellera Biologics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Abcellera (USA Stocks:ABCL) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR. Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Abcellera Biologics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board
This overview frames the main risk lens used to think about the instrument before capital is committed. It works as a simple reference for investors who want to understand risk-adjusted performance before trading. The danger of trading Abcellera Biologics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Abcellera Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a riskier asset than Abcellera Biologics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Abcellera Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-month bill.
More Resources for Abcellera Stock Analysis
Understanding Abcellera Biologics starts with reviewing its financial statements and long-term patterns. Selected reports below provide context for Abcellera Stock: